Hims & Hers Health Inc - HIMS STOCK NEWS

Define Ventures, a major early-stage health tech venture capital firm, has appointed Carolyn Magill as venture partner. Magill brings 25 years of experience in healthcare, having served as CEO of Aetion and Remedy Partners, and held executive positions at Evolent Health and UnitedHealth Group.

Magill joins existing venture partners Bruce Broussard (former Humana CEO) and Frank Williams (Evolent Health co-founder) to support Define's portfolio companies. The firm, managing $800 million in assets, invests in seed to series B stage companies and has backed notable ventures like Hims & Hers.

Her expertise spans payer, provider, and pharmaceutical sectors, with particular focus on data and AI applications. At Aetion, she led a platform transforming real-world data into regulatory-grade evidence, while at Remedy Partners she oversaw bundled payments software and services.

Hims & Hers Health (NYSE: HIMS) reported strong financial results for Q4 and full year 2024. The company achieved revenue of $1.5 billion in 2024, representing a 69% year-over-year increase, with net income of $126 million and Adjusted EBITDA of $177 million.

Subscriber base grew to 2.2 million, up 45% year-over-year. Revenue excluding GLP-1 offering increased 43% to over $1.2 billion. For Q4 2024, revenue was $481.1 million, up 95% from Q4 2023, with net income of $26 million.

The company provided guidance for 2025, projecting revenue between $2.3-2.4 billion and Adjusted EBITDA of $270-320 million. For Q1 2025, revenue is expected to be $520-540 million with Adjusted EBITDA of $55-65 million.

Hims & Hers Health has acquired a US-based peptide facility in California, strengthening its domestic supply chain capabilities. This acquisition follows previous purchases of 503A and 503B facilities, further verticalizing the company's operations. The move aims to enhance the company's ability to deliver personalized medications and meet growing demand from American consumers.

The peptide facility acquisition positions Hims & Hers to explore future innovations in areas including preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistances. The transaction, which closed in early February, demonstrates the company's commitment to maintaining US-based operations for better control over cost, availability, and quality standards.

Hims & Hers Health has announced the acquisition of Sigmund NJ (Trybe Labs), an at-home lab testing facility, to introduce comprehensive lab testing capabilities through its platform. The acquisition, funded through cash on hand, will enable the company to support at-home blood draws and whole body testing using blood lancets.

The new service will allow customers to test hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health. This expansion will facilitate the company's entry into new clinical categories including low testosterone, perimenopausal and menopausal support. The de-identified lab data will also enhance the company's AI developments, including MedMatch.

The integration of lab testing aims to provide more precise clinical decision-making and personalized treatment plans. Hims & Hers plans to roll out at-home testing to customers over the next year.

Hims & Hers Health (NYSE: HIMS) has launched two new customer-focused initiatives: the Health Collective and the Community Member Council. The Health Collective is an ambassador program open to active customers, allowing them to connect with other members, share experiences, and get early access to new products. The Community Member Council consists of 15 hand-selected members who will directly influence the platform's future development by providing feedback on products, services, and experiences.

These programs align with the company's mission to enhance global health and wellness while building stronger relationships with customers. According to Chief Commercial Officer Mike Chi, the initiatives will help improve customer experience and care by actively incorporating user feedback into the platform's development.

Hims & Hers Health (NYSE: HIMS), the leading health and wellness platform, has announced it will release its fourth quarter and full year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call to discuss the results at 5:00 p.m. ET on the same day.

Investors can access the conference call by dialing (888) 510-2630 (U.S.) or (646) 960-0137 (international) with conference ID 1704296. A live audio webcast will be available on the company's investor relations website and archived for one year.

Additionally, the company's management team will participate in the Morgan Stanley Technology, Media & Telecom Conference on March 4, 2025 in San Francisco.

Hims & Hers (NYSE: HIMS) has released 'The Shape of America' report, providing insights into Americans' relationship with weight in 2024. Based on a survey of 5,000 adults, key findings reveal that 83% of Americans are not at their desired weight, with respondents wanting to lose an average of 42 pounds. The study shows that 75% of Americans think about their weight daily, with 14% considering it constantly.

Notable findings include: 85% believe weight loss would improve major life aspects, 81% think they'd save money on household expenses if they lost weight, and 47% attempt weight loss yearly, seasonally, or constantly. The report also highlights that individuals with obesity are 50% more likely to skip work due to their weight and 2.5X more likely to withdraw from activities and social plans.

Hims & Hers Health (NYSE: HIMS) has been named to Inc.'s 2024 Best in Business list in the Health Products category. The recognition celebrates companies that have achieved significant milestones and made substantial impacts on their industries and society.

The company, which focuses on providing access to high-quality, affordable personalized care, has demonstrated remarkable business growth and customer impact across its platform. Their core specialties include sexual health, dermatology, mental health, and weight loss. Hims & Hers leverages innovative solutions in technology, operations, and customer experience to improve healthcare accessibility and standards.

Inc.'s Best in Business list acknowledges companies from various sectors, including technology, healthcare, finance, and retail, that have achieved exceptional execution in areas such as customer expansion, product launches, and increased market share.

Hims & Hers Health (NYSE: HIMS) has expanded its weight loss offerings by introducing daily meal replacement bars and shakes, available through subscription starting at $110 per month. The new nutrition products, developed by registered dietitians, include protein-packed bars with 15g of protein and shakes containing 27-30g of protein, along with essential vitamins and minerals. The comprehensive weight management program includes personalized treatment plans, medication management, nutritional guidance, weekly meal plans, and 24/7 access to care teams through their platform.